Search

Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management

Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management. Click here to find out more information.

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.

The NCD Initiative

Boehringer Ingelheim India signs MoU with the Government of Maharashtra, to strengthen stroke care in the state

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services. Find out more.

Jardiance® (empagliflozin) now approved in India for treatment of chronic kidney disease

Jardiance® (empagliflozin) now approved in India

About Us

Human Health

Animal Health